Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dusquetide - Soligenix

Drug Profile

Dusquetide - Soligenix

Alternative Names: Dusquetide; IDR-1; Innate defense regulator-1; SGX-94; SGX-942; SGX-943

Latest Information Update: 19 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of British Columbia
  • Developer Soligenix; The Childrens Hospital of Philadelphia
  • Class Anti-inflammatories; Antibacterials; Peptides; Proteins
  • Mechanism of Action Immunomodulators; SQSTM1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoproliferative disorders; Acute radiation syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Stomatitis
  • Preclinical Bacterial infections; Lymphoproliferative disorders; Melioidosis
  • No development reported Acute radiation syndrome

Most Recent Events

  • 15 Aug 2019 Soligenix receives phase-I SBIR grant from the National Institute of Dental and Craniofacial Research for dusquetide development in Stomatitis (In children, In infants, In adolescents)
  • 09 Apr 2019 Paediatric Committee (PDCO) of EMA approves Soligenix' Paediatric Investigation Plan (PIP) for dusquetide in Stomatitis (Chemotherapy-induced)
  • 09 Apr 2019 Soligenix receives a US patent allowance for Dusquetide related analogues in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top